RxDoctor Payments Data

Munish Goyal, MD

Cardiovascular Disease · Birmingham, ALNPI 1902845829

Payments from drug & device makers

$4,015in general payments, 2019–2025

Across 83 payments — averaging $48.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Novartis$535
  • Medtronic$358
  • Abiomed$251
  • Shockwave Medical, Inc$156
  • Inari Medical, Inc.$148
  • plus $524 from 9 others

What the payments were for

  • Travel & lodging$1,49337%
  • Food & beverage$2,52163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,015 in reported general payments places this provider in the 55th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$211,407
Medicare patients
536
Services billed
2,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban510$494,328
XareltoRivaroxaban131$135,420
EntrestoSacubitril/Valsartan61$62,386
Repatha SureclickEvolocumab85$62,342
Dabigatran EtexilateDabigatran Etexilate Mesylate67$19,464
Ranolazine ErRanolazine101$8,181
Atorvastatin Calcium448$6,684
Metoprolol Succinate359$5,860
Flecainide Acetate54$4,625
Midodrine Hcl56$4,355
ClopidogrelClopidogrel Bisulfate294$4,037
Amlodipine Besylate486$3,791
Amiodarone Hcl114$3,779
Atenolol-ChlorthalidoneAtenolol/Chlorthalidone138$3,579
Propafenone Hcl ErPropafenone Hcl12$3,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$494,328510 claims
Johnson & JohnsonXarelto$13$135,420131 claims
NovartisEntresto$535$62,38661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →